DENTSPLY SIRONA Inc. (XRAY) Form 8-K — Nov 5, 2026
Dentsply Sirona (XRAY) reported Q3 2026 net sales of $836 million, down 7.6% year over year, with a GAAP diluted loss per share of $0.01 and adjusted EPS of $0.29, down 29.4% from $0.42. Adjusted EBITDA fell 13.3% to $146 million, and results included a one-time $39 million benefit from a revised inventory accounting estimate. Q3 operating cash flow dropped to $32 million from $79 million, with free cash flow at zero. Bright spots included record quarterly sales for Wellspect Healthcare with 10.1% reported growth, plus $25 million returned to shareholders via buybacks year to date.
Key figures
- Eps
- -$0.01 GAAP diluted; $0.29 adjusted
- Revenue
- 836000000
- Guidance
- FY2026 net sales ~$3.5B; adjusted EPS $1.20-$1.30 (excl. $0.17 one-time tariff refund benefit)
- Net Income
- -2000000
- Total Debt
- 2200000000
- Revenue Yoy
- -7.6%
- Total Assets
- 5190000000
- Cash Position
- 195000000
- Adjusted ebitda
- $146M (17.3% margin)
- Free cash flow q3
- $0M
- Adjusted ebitda yoy
- -13.3%
- Operating cash flow q3
- $32M vs $79M prior year
- Share repurchases ytd 2026
- $25M
- Q3 accounting estimate benefit
- $39M
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.